Nutlin-3

For research use only. Not for use in humans.

製品コードS1061

Nutlin-3化学構造

CAS No. 890090-75-2

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 32700
JPY 20200
JPY 30200
JPY 63400
JPY 163000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

文献中Selleckの製品使用例(72)

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SMMC-7721  MVzGeY5kfGmxbjDBd5NigQ>? MWixNEDPxE1? M3jpbVM3KGh? NYjDZ5lVTE2VTx?= MVzkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MlPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OE[zNVIoRjJ2Mki2N|EzRC:jPh?=
HuH-7 MXrBdI9xfG:|aYOgRZN{[Xl? M{HhblIxKM7:TR?= MkjSOFghcA>? NVjFdIVQTE2VTx?= MVLpcoR2[2W|IHHwc5B1d3Orcx?= NW\3N|RwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
SMMC-7721  MYfBdI9xfG:|aYOgRZN{[Xl? NUDLdIJ{OjBizszN MXm0PEBp M3\xZ2ROW09? NWHXdpVQcW6mdXPld{BieG:ydH;zbZM> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
HuH-7 NELNTIpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{npT|EvOjVvMkCg{txO MlXTNlQwPDhxN{KgbC=> NIG5XmpFVVOR NGS4fXJqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NXSyRlB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
SMMC-7721  M1nlW2NmdGxiVnnhZoltcXS7IFHzd4F6 NXSxOnkzOS5{NT2yNEDPxE1? M1XDflI1NzR6L{eyJIg> MWHEUXNQ M4O0dYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M2TZ[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki2N|EzLz5{NEK4OlMyOjxxYU6=
RKO NIT1Z4xHfW6ldHnvckBCe3OjeR?= M1yz[|IxKM7:TR?= MVOyOEBp MmrZbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= Mmn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Nk[wNFcoRjJ2M{[2NFA4RC:jPh?=
U2OS  MX;GeY5kfGmxbjDBd5NigQ>? NWPTU|FuOjBizszN MXKyOEBp NEDDNo1qdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NVTTTGZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlYxODdpPkK0N|Y3ODB5PD;hQi=>
RKO NGrNd2xHfW6ldHnvckBCe3OjeR?= MYqyNEDPxE1? NGfyNYEzPCCq NE\hTnNqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NEfBeoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
U2OS  MoXVSpVv[3Srb36gRZN{[Xl? MV2yNEDPxE1? MX:yOEBp MYDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NFnIZmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
MOLM NGXHZ5pHfW6ldHnvckBCe3OjeR?= Ml:xNVAh|ryP M{nKTFI1KGh? NYnKZphZfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NE\iVW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3N|U3Oid-MkS0O|M2PjJ:L3G+
OCI NGj3O4RHfW6ldHnvckBCe3OjeR?= M2nDWlExKM7:TR?= NG\ud3UzPCCq MkmxeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{O1OlIoRjJ2NEezOVYzRC:jPh?=
BeWo MWDBdI9xfG:|aYOgRZN{[Xl? MlLsN|AhyrWP NGHseYgzPCCq MnfDbY5kemWjc3XzJIFxd3C2b4Ppdy=> NFjZRmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5PFE2PCd-MkS0PVgyPTR:L3G+
BeWo MWXGeY5kfGmxbjDBd5NigQ>? NXfxe4tPOzBiwsXN NUDIenE1OjRiaB?= NEj4cWVqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> NUPpZndSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVgyPTRpPkK0OFk5OTV2PD;hQi=>
MOML13 NHq4S25HfW6ldHnvckBCe3OjeR?= M2myflEx|ryP NFLEbHIzNzRiaB?= NGG3PWFqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
AML3 MWjGeY5kfGmxbjDBd5NigQ>? NGXhR3kyOM7:TR?= M{HOSVIwPCCq MXLpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= Mk\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
AML2 Mn6zSpVv[3Srb36gRZN{[Xl? MoXGNVDPxE1? NED4eIIzNzRiaB?= MlP2bY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NXTEcoo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
MOML13 MmHaRZBweHSxc3nzJGF{e2G7 MUmyM|ExKM7:TR?= MUiyOE81QCCq Mlv6bY5lfWOnczDhdI9xfG:|aYO= M2LlV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW5O|Q6Lz5{NE[1PVc1QTxxYU6=
AML2 MmTZRZBweHSxc3nzJGF{e2G7 M2n4blIwOTBizszN MoTFNlQwPDhiaB?= MkPGbY5lfWOnczDhdI9xfG:|aYO= NF;RWHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1PVc1QSd-MkS2OVk4PDl:L3G+
U2OS  MXLGeY5kfGmxbjDBd5NigQ>? MV2yNEDPxE1? MVyyOEBp MVTpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ NE\zSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2O|I2QSd-MkS4OlczPTl:L3G+
Hep3B NWnXO2lTSXCxcITvd4l{KEG|c3H5 Ml3lbY5lfWOnczDhdI9xfG:|aYO= NVPle|ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
Huh-7 NWDLSmZrSXCxcITvd4l{KEG|c3H5 MmDYbY5lfWOnczDhdI9xfG:|aYO= NWTUPWtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
SMMC7721 MYrBdI9xfG:|aYOgRZN{[Xl? NEC5S2dqdmS3Y3XzJIFxd3C2b4Ppdy=> NVXUUFNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
HepG2 NF;6TFFCeG:ydH;zbZMhSXO|YYm= NXvrVZUxcW6mdXPld{BieG:ydH;zbZM> NVTZR495RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
Hep3B MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:3NkBp MWjEUXNQ MYLJR|UxRTJyLkG4JOKyKDFwOESg{txO MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
Huh-7 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaO|IhcA>? M1;OWWROW09? M{[2emlEPTB;M{OuPVYhyrFiMz65JO69VQ>? NV;Gd|ZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
SMMC7721/Ac MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq2RoI4OiCq NG\kbI1FVVOR MX3JR|UxRTV3LkKxJOKyKDVwMEOg{txO M4ThUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
SMMC7721 M2XZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK3NkBp M1L0fmROW09? NH3lZ29KSzVyPUOxMlI5KMLzIESuNkDPxE1? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
HepG2/As NXLydnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3O|IhcA>? NF3R[pJFVVOR MlzUTWM2OD14OD6xN{DDuSB7Lk[g{txO NETkbI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
HepG2 NU\FcGpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHhSG1EPzJiaB?= M2S2PWROW09? MkLZTWM2OD1|NT64OkDDuSB{Lkmg{txO NEXDeJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
MOLM-13 NHG3NnJHfW6ldHnvckBCe3OjeR?= MVe2xsDPxE1? NWXGN3JWPiCq NFjtcoxFVVOR NXHzT3Fi\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> Mn3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEWwPFIoRjJ2OEi1NFgzRC:jPh?=
MOLM-13 MWjGeY5kfGmxbjDBd5NigQ>? MUe2xsDPxE1? NYnTd45XOC16IHi= NULsVW1bTE2VTx?= MmDNbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NUC4Nkc,OjR6OEWwPFI9N2F-
115 NXjOS2JoTnWwY4Tpc44hSXO|YYm= M2HvWVUh|ryP NG\UPZM1QCCq NWP2R3BSTE2VTx?= M{fNTIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M{LMdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
A498 MWLGeY5kfGmxbjDBd5NigQ>? MWe1JO69VQ>? NH\xSpQ1QCCq NHjXXm9FVVOR MofGbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
Caki-2 M17Lb2Z2dmO2aX;uJGF{e2G7 M3XPTVUh|ryP Moq5OFghcA>? NFnGTmdFVVOR M4ixU4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NH;x[YM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
ACHN MkjVSpVv[3Srb36gRZN{[Xl? NWnVTHhvPSEQvF2= MlH3OFghcA>? NYTTOY15TE2VTx?= NYjsdolXcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NXXNeIFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
115 NXjXNlI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC1JO69VQ>? NFLjeVk1QCCq M4naZmROW09? NHP1NVBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NEPqZow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
A498 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HqUFUh|ryP M3zLb|Q5KGh? NFzoXJRFVVOR NHryeGlqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NXrObodZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2wbYU2KM7:TR?= MoWwOFghcA>? NV20N4dnTE2VTx?= NH;GOINqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M{\KflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
ACHN MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLmOUDPxE1? NETWVnQ1QCCq NEDXNJlFVVOR MXrpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M{TSblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
115 NGLPfGxHfW6ldHnvckBCe3OjeR?= Ml;FNE42NzFxNTFOwG0> MmXlOFghcA>? NXrx[|dJTE2VTx?= MlLqcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M1jTNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
A498 MV7GeY5kfGmxbjDBd5NigQ>? NWrCNpp4OC53L{GvOUDPxE1? NYDuVpZ[PDhiaB?= M3TkTWROW09? NWHxOIx3dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= M{LiTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
Caki-2 MVLGeY5kfGmxbjDBd5NigQ>? NUnseI1LOC53L{GvOUDPxE1? MljJOFghcA>? M4rZPWROW09? MlTpcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
ACHN M3fEb2Z2dmO2aX;uJGF{e2G7 MUGwMlUwOS93IN88US=> MkLQOFghcA>? MVjEUXNQ NHrzdmtt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MofEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
117 NHjtWm9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV3rdVd1OC53LUGwJO69VQ>? MWSwMVYh\A>? M2HjdGROW09? M4eyU4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1\YUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
115 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1LET|AvPS1zMDFOwG0> M33nflAuPiCm NILNWWRFVVOR M3;rcIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFmxeJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
A498 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoTiNE42NTFyIN88US=> M{HjclAuPiCm MXXEUXNQ NHf6eJZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4\FWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
Caki-2 NFzxN4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NULnV5R1OC53LUGwJO69VQ>? M1LoeVAuPiCm M{n0ZmROW09? NIrhPGpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUTsWVcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
ACHN NUfNZodSS2WubDDWbYFjcWyrdImgRZN{[Xl? NUHpbppFOC53LUGwJO69VQ>? MXSwMVYh\A>? NHfOPGpFVVOR MWXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
MCF7  NY\xbI1MTnWwY4Tpc44hSXO|YYm= M2XObFIvPSEEtV2= NHr5PWQ1QCCq NWDFT|NwTE2VTx?= M2fIRoRm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOEW5NFIoRjJ3MEi1PVAzRC:jPh?=
MCF7  M{PveGNmdGxiVnnhZoltcXS7IFHzd4F6 NVy4NmdCOi53INM1US=> MlnxOUBl MkXWSG1UVw>? M3jqfJNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= NHrEcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4OVkxOid-MkWwPFU6ODJ:L3G+
RAW 264.7 NUjMd|FoTnWwY4Tpc44hSXO|YYm= MYixNOKh|ryP M4nQR|MxKG2rbh?= NGm3dm1qdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NHTzeWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
RAW 264.7 MV3GeY5kfGmxbjDBd5NigQ>? MnzZNVDDqM7:TR?= MYGzNEBucW5? NFfuXlFz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 NYHocI9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO|I2PDdpPkK1NVczPTR5PD;hQi=>
RAW 264.7 MUnGeY5kfGmxbjDBd5NigQ>? M{Tkc|ExyqEQvF2= NIfEVJc{OCCvaX6= NV;yWm1IeHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU NH;yWm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
SUM102PT M{HaNGZ2dmO2aX;uJGF{e2G7 Mmm0NVDDqM7:TR?= NITOO2UzPCCq M1\HN2ROW09? MkDRbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
SK-BR-7 NFfLVpVHfW6ldHnvckBCe3OjeR?= MXixNOKh|ryP NXfNTohKOjRiaB?= M1nUbGROW09? MmLFbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
MCF-10CA1a NI[3Oo1HfW6ldHnvckBCe3OjeR?= NUX4WVVTOTEEoN88US=> M2P2Z|I1KGh? NF7TcmdFVVOR MUnpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M1zFOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3O|I6Lz5{NUK1O|czQTxxYU6=
MCF-10CA1a MUHGeY5kfGmxbjDBd5NigQ>? MlHLNVDDqM7:TR?= NWi0OmtyOjRiaB?= M{DXUWROW09? MkHE[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? NYfv[WR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOVc4OjlpPkK1NlU4PzJ7PD;hQi=>
MCF-10A1  M36xfGZ2dmO2aX;uJGF{e2G7 NEDCeHMyOMLizszN MlT3NlQwPDhiaB?= NWLNSWZ4TE2VTx?= NVLHfFBwcW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10CA1a MnTBSpVv[3Srb36gRZN{[Xl? NVTOcplYOTEEoN88US=> MlzPOFghcA>? M1fDb2ROW09? MlTubY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
HCT116  Ml;RSpVv[3Srb36gRZN{[Xl? NVTYNFVmOTBiwsXN M1;SO|I1KGh? NXjBOHk5[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 MnrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|OECwOVUoRjJ3M{iwNFU2RC:jPh?=
A2780 Ml24SpVv[3Srb36gRZN{[Xl? M3HGVVExyqEQvF2= NX;CT|RTOjGqwrC= M3TjWWROW09? M1jMPYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
NCI-H23 MWfGeY5kfGmxbjDBd5NigQ>? NFjCOpYyOMLizszN MkHTNlFpyqB? M1;2e2ROW09? NFO5b25l\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NVm5S3BkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlY2PDhpPkK1OFI3PTR6PD;hQi=>
A2780 MkDTSpVv[3Srb36gRZN{[Xl? M{fMcVExyqEQvF2= Moq5NlFpyqB? MlrTSG1UVw>? Ml61bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Mk[1OFgoRjJ3NEK2OVQ5RC:jPh?=
NCI-H23 MkP2SpVv[3Srb36gRZN{[Xl? NWe1T25IOTEEoN88US=> NHz6TIEzOWkEoB?= NXTrNI4yTE2VTx?= M4f4XYlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
OVCAR10 NUDNc4VCTnWwY4Tpc44hSXO|YYm= M124dlExyqEQvF2= NG\reYgzOWkEoB?= M3HZN2ROW09? Ml7WbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> Mlm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Mk[1OFgoRjJ3NEK2OVQ5RC:jPh?=
MCF-7 M2fTU2Z2dmO2aX;uJGF{e2G7 NX;uW3BNOTEEoN88US=> NUfMSplLOC1{NDDo NGfEOGVqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= M4PTbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEiyN|c{Lz5{NUS4NlM4OzxxYU6=
SMMC-7721 NVXzOXlQTnWwY4Tpc44hSXO|YYm= MnzkNVAh|ryP NWPWV2NHOzZiaB?= M2T5VWROW09? NGPIfVdk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? M3f6[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUS0N|YyLz5{NUW0OFM3OTxxYU6=
SMMC-7721 MYfGeY5kfGmxbjDBd5NigQ>? MmD3NVAh|ryP NIr5Z|M1QCCq M3XhVmROW09? M1nLXYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> M3;QdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUS0N|YyLz5{NUW0OFM3OTxxYU6=
SMMC-7721 MXTGeY5kfGmxbjDBd5NigQ>? M3nOTFExKM7:TR?= NHTKdWo1QCCq M13aUGROW09? NVP5bIk2cW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2NEO2NUc,OjV3NESzOlE9N2F-
SMMC-7721 MX3GeY5kfGmxbjDBd5NigQ>? NHrTPIQyOCEQvF2= MYO0PEBp NYO5UnBITE2VTx?= M4fHPYNifXOnczDEUmEhTFOEIHThcYFo\Q>? MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NESzOlEoRjJ3NUS0N|YyRC:jPh?=
DU4475  NYG3VmxSTnWwY4Tpc44hSXO|YYm= MorrOU8yOC9{MDFOwG0> NHfPflQzPMLiaB?= MWDkc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5 NVXh[|ByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OFcyPzRpPkK1OVQ4OTd2PD;hQi=>
MCF-7  MlvPSpVv[3Srb36gRZN{[Xl? NIjCUoQyOMLizszN MYjEUXNQ NXrlO29qcW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi M1TTSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CyO|A{Lz5{NUewNlcxOzxxYU6=
C2C12 NGXidm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxNOKh|ryPwrC= NVftboY{OjRxNEivO|IhcA>? NWDrNoxyTE2VTx?= MmfibY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NWrpXldSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O|E4QTRpPkK1PFcyPzl2PD;hQi=>
L6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNOKh|ryPwrC= NGPYbpQzPC92OD:3NkBp M{XaXGROW09? M3zHR4lvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? NYTUUWFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O|E4QTRpPkK1PFcyPzl2PD;hQi=>
CRL-5908 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsNlQhcA>? NF\LN|dKSzVyPUO4MlcyKMLzIEKuOFMh|ryP M1vwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1NlMxLz5{NkGyOVI{ODxxYU6=
A549-920 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjUXYZJOjRiaB?= MmjvTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? NYLzUpZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzOzBpPkK2NVI2OjNyPD;hQi=>
A549-NTC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXkO44zPCCq NEfnOXhKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NWXkVlZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzOzBpPkK2NVI2OjNyPD;hQi=>
A549 MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYeyOEBp MX;JR|UxRTF5Lk[4JOKyKDRwNUKg{txO M2PtVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1NlMxLz5{NkGyOVI{ODxxYU6=
C666-1 M4e2cGFxd3C2b4Ppd{BCe3OjeR?= NFnQdWcyOCEEtV2= M{PVU|Q5Nzd{IHi= MkK5SG1UVw>? NHfieZZ{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> M1zoWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
C666-1  NYTEenV3TnWwY4Tpc44hSXO|YYm= MV6xNEDDvU1? NGH0eZYzPCCq NYLhSoNtTE2VTx?= MmXXZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3MkW3OUc,OjZ{NUK1O|U9N2F-
C666-1 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH\6N2gyOCEEtV2= MXm0PEBp Ml;6SG1UVw>? NWTHcFl2e2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu M3XwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
C666-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF7Lkm1xtE5Njl|IN88US=> MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
NP460 M2f2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nmS2lEPTB;MkKuPFXDuTFwMUig{txO M{ezSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
NP69 M1jPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfLO4tKSzVyPUOxMlY6yrF{LkW0JO69VQ>? MmHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
MCF7 NGizeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5N|XDqM7:TR?= M3HEeFQ5yqCq M3TGfYJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? M{Poe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WwOVY2Lz5{NkO1NFU3PTxxYU6=
HuH-7 NXSzWXN2TnWwY4Tpc44hSXO|YYm= MkPJNVAh|ryP M3zQT|M3KGh? MVjEUXNQ MVfkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
AT2 MYPGeY5kfGmxbjDBd5NigQ>? MUi1M|ExKM7:TR?= NFnEc5lt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M2\PO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
REH NV7R[XNZTnWwY4Tpc44hSXO|YYm= NWjzXJV2PS9zMDFOwG0> MoLMcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NV;IUpBuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
UoCB6 M1HOXGZ2dmO2aX;uJGF{e2G7 MV:1M|ExKM7:TR?= NXHaW3VzdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
AT2 MknvR4VtdCCYaXHibYxqfHliQYPzZZk> M3O1[lAuOjVizszN NWfaPIdRcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4ruXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
REH MlX6R4VtdCCYaXHibYxqfHliQYPzZZk> NH7GbXMxNTJ3IN88US=> NVixNoZNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
UoCB6 Mme0R4VtdCCYaXHibYxqfHliQYPzZZk> M1HaeFAuOjVizszN MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVPiVJJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
A2780 NYPTOJN{TnWwY4Tpc44hSXO|YYm= MYC1M|ExNzJyIN88US=> M1nqb|I1KGh? MVT1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MmjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
H460 NECxdWNHfW6ldHnvckBCe3OjeR?= NH\sUWQ2NzFyL{KwJO69VQ>? NGXJUlYzPCCq NID6Znp2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MnnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
Lovo  NYqwfmJ1TnWwY4Tpc44hSXO|YYm= MUC1M|ExNzJyIN88US=> NV3Z[WZqOjRiaB?= NXG2PXd7fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
A2780 NHvy[pFCeG:ydH;zbZMhSXO|YYm= MX21M|ExNzJyIN88US=> MUOyOEBp NV\rUGF7\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|NkG0O{c,OjRzM{[xOFc9N2F-
H460 MnTQRZBweHSxc3nzJGF{e2G7 MkDuOU8yOC9{MDFOwG0> M3fnVlI1KGh? NU\qbJBG\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NUfTbFF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|YyPDdpPkK0NVM3OTR5PD;hQi=>
Lovo  MVPBdI9xfG:|aYOgRZN{[Xl? NWjBRnFYPS9zMD:yNEDPxE1? M2PQSlI1KGh? MV3lcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> M2f2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
U87MG MlWySpVv[3Srb36gZZN{[Xl? MoLSNVAhdWmwcx?= Mn;TRolv\GmwZzDh[oZqdmm2eTD0c{BOTE1{IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUWROOi:yNUOgdJJwfGWrbjDpcpRmemGldHnvckBi\nSncjCxNEBucW6|IHL5JJF2[W62aYTheIl3\SC|YX7ke4lkcCCrbX31co8h[XO|YYmsJGlEPTBiPTCwMlExPDVizszNMi=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB3MEe4Nkc,OjdyNUC3PFI9N2F-
U87MG NHmwNm1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVu0PEBpenN? NUHMemNjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCyNUOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IE[uOUDPxE1w NEeyfFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C1NFc5Oid-MkewOVA4QDJ:L3G+
U343MG M2DDbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml65OFghcHK| NIDlTWZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWzOFNOTyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCyNUOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEGyMlYh|ryPLh?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB3MEe4Nkc,OjdyNUC3PFI9N2F-
SW620 MkeyR5l1d3SxeHnjbZR6KGG|c3H5 MVi3NkBpenN? NYHXdplKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1d4MkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwM{ig{txONg>? NVrzU2dYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
A549 MWPDfZRwfG:6aXPpeJkh[XO|YYm= M{O5ZlczKGi{cx?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCwMlQyKM7:TT6= NV7t[296RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
SJSA1 MVLDfZRwfG:6aXPpeJkh[XO|YYm= NWDOTWl1PzJiaILz M1nvRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNLW0FzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAyNjhzIN88UU4> NHnuRlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
HCT116 NIjOW2REgXSxdH;4bYNqfHliYYPzZZk> NGm2XW84OiCqcoO= MkO1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA1NjZ|IN88UU4> NVyxVnhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
PC3 MYrDfZRwfG:6aXPpeJkh[XO|YYm= MYW3NkBpenN? NHvSR2xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOzdizszNMi=> Ml7pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
- 合併

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験：

[1]
- 合併
  • 細胞株： HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度： Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間： 8, 24, and 48 hours
  • 実験の流れ：

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験：

[1]
- 合併
  • 動物モデル： Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 投薬量： 200 mg/kg
  • 投与方法： Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4
CAS No. 890090-75-2
Storage powder
in solvent
別名 N/A
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
投与量 mg/kg 動物平均体重 g 投与体積（動物毎） ul 動物数 匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答：

    It is a racemate.

selleck catalog

Mdm2シグナル伝達経路

相関Mdm2製品

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • NSC 207895

    NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3a

    Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • Nutlin-3b

    Nutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • Z-VAD-FMK

    Z-VAD-FMK (Z-VAD(OMe)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • Navitoclax (ABT-263)

    Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID